Trial reportBlood2018
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Erratum issued 8 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 8 registered trials, which are not on this map. Cited by 449 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
449citing papers in PubMed, 5 pooled it
87.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Toxicity of Blinatumomab in the French Compassionate Use Program (ATU) for Adult Patients With B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Refractory, in Relapse, or With Positive Minimal Residual Disease.
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
A Multicenter ,Prospective, Randomized Clinical Trial of Blinatumomab As a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
The Regimen of Blinatumomab and Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating Precursor B Cell Acute Lymphoblastic Leukemia: A Phase II, Single Arm and Multicenter Study
NCT06607419 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Blinatumomab Combined With Reduced-dose Chemotherapy in Treating Precursor B Cell Acute Lymphoblastic Leukemia: a Phase II, Single Arm and Multicenter Study
Daratumumab for Minimal Residual Disease Eradication in T-Acute Lymphoblastic Leukemia - A Phase 2 Study
Who cites it
449 citing papers in PubMed, 5 syntheses or guidelines pooled it, 818 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.Blood advances · 2026Guideline
- Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.Frontiers in immunology · 2026Pooled it
- Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies.Frontiers in immunology · 2026Pooled it
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.Bone marrow transplantation · 2025Guideline
- Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.Blood cancer journal · 2026Trial
- Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.Journal of hematology & oncology · 2026Trial
- Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.Annals of hematology · 2026Trial
- Trial
- Trial
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.The New England journal of medicine · 2025Trial
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.The New England journal of medicine · 2024Trial
- Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.Cancer medicine · 2024Trial
- Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics.Oncoimmunology · 2026Review
- Cell-delivered CD3×CD19 T-cell engager by STAb-T19 cells mediates leukemia clearance with limited systemic exposure.Journal for immunotherapy of cancer · 2026Article
- Next-generation immune cell engagers for B cell depletion in autoimmune diseases.Nature reviews. Drug discovery · 2026Review
- Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL.Journal for immunotherapy of cancer · 2026Article
- Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplantation.Blood advances · 2026Article
389 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
18 authors at 14 institutions in 6 countries.
Nicola GökbugetUniversity Hospital, Frankfurt, Germany.
Hervé DombretUniversity Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France.ORCID 0000-0003-4824-3880
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, Verona University, Verona, Italy.ORCID 0000-0003-0716-1686
Albrecht ReichleUniversity Hospital Regensburg, Regensburg, Germany.ORCID 0000-0002-1821-7887
Carlos GrauxUniversité Catholique de Louvain, CHU UCL Namur (Godinne), Yvoir, Belgium.ORCID 0000-0001-9236-3623
Christoph FaulUniversity Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen, Tübingen, Germany.
Helmut DiedrichDepartment of Hematology and Oncology, Medizinische Hochschule, Hannover, Germany.ORCID 0000-0001-8449-7023
Max S ToppMedizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Monika BrüggemannKlinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.ORCID 0000-0001-5514-5010
Heinz-August HorstKlinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Violaine HavelangeCliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Julia StieglmaierAmgen Research (Munich), GmbH, Munich, Germany.
Hendrik WesselsAmgen Research (Munich), GmbH, Munich, Germany.
Vincent HaddadAmgen, Ltd., Cambridge, United Kingdom.
Jonathan E BenjaminAmgen, Inc., Thousand Oaks, CA; and.ORCID 0000-0002-3864-638X
Gerhard ZugmaierAmgen Research (Munich), GmbH, Munich, Germany.
Dirk NagorsenAmgen, Inc., Thousand Oaks, CA; and.
Ralf C BargouComprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany.ORCID 0000-0002-1221-7421
Amgen (Germany) · DEAmgen (United States) · USUniversity Hospital Schleswig-Holstein · DEAmgen (United Kingdom) · GBCliniques Universitaires Saint-Luc · BEComprehensive Cancer Center Mainfranken · DEDélégation Paris 7 · FRGoethe University Frankfurt · DEMedizinische Hochschule Hannover · DEUCLouvain · BEUniversitätsklinikum Tübingen · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Regensburg · DEUniversity of Verona · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10
Indexed as
AdolescentAdultAgedAntibodies, BispecificDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm, ResidualPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRecurrenceSurvival RateAntibodies, Bispecificblinatumomab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03751072ClinicalTrials.gov
NCT05289687ClinicalTrials.gov
NCT05519579ClinicalTrials.gov
NCT05559450ClinicalTrials.gov
NCT06554626ClinicalTrials.gov
NCT06607419ClinicalTrials.gov
and 2 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.